Q2 2026 Elevance Health Inc Earnings Call Transcript
Key Points
- Elevance Health Inc (ELV) delivered second-quarter results ahead of expectations, reflecting favorable benefit expense performance and disciplined execution.
- The company raised its 2026 adjusted diluted earnings per share guidance to at least $27, with confidence in returning to at least 12% adjusted EPS growth in 2027.
- Medicare Advantage performance improved due to deliberate actions, with a path to at least a 2% operating margin this year.
- Investments in AI-enabled capabilities and Carelon are becoming more meaningful contributors to the company's growth.
- Elevance Health Inc (ELV) is making targeted investments to strengthen medical cost management, member engagement, and provider connectivity, which are expected to enhance long-term performance.
- The Medicaid environment remains dynamic, with a negative operating margin outlook of approximately -1.75% for the full year.
- Elevance Health Inc (ELV) plans to exit additional Medicaid markets over the next 12 to 18 months where sustainable performance is not achievable.
- The company is not assuming a material improvement in Medicaid trend in the second half of the year, maintaining a prudent outlook.
- Elevance Health Inc (ELV) is facing elevated cost pressures in categories such as behavioral health, specialty pharmacy, and outpatient surgery.
- The company is making one-time, non-recurring investments in 2026, which may not provide immediate returns and could impact short-term financials.
Ladies and gentlemen, thank you for standing by and welcome to the Elevance Health second-quarter earnings conference call. (Operator Instructions) As a reminder, today's conference is being recorded.
I would now like to turn the conference over to the company's management. Please go ahead.
Good morning, and welcome to Elevance Health second-quarter 2026 earnings conference call. My name is Nathan Rich, Vice President of Investor Relations. With us on the earnings call are Gail Boudreaux, President and CEO; Mark Kaye, our CFO; Felicia Norwood, our Chief Health Benefits Officer; Morgan Kendrick, President of our Commercial Health Benefits Business; and Aimee Dailey, President of our Government Health Benefits Business.
Gail will begin with a review of our second quarter results, the progress we have made against our strategic priorities, and targeted investments designed to strengthen the enterprise over time. Mark will then discuss our financial performance and outlook in
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
